medigraphic.com
ISSN 2078-7170 (Digital)

2021, Número 2

<< Anterior Siguiente >>

CorSalud 2021; 13 (2)


Diabetes mellitus tipo 2: Consideraciones sobre riesgo cardiovascular y rehabilitación cardiovascular. Primera parte

Pérez YLM, Gutiérrez LA, Rodríguez BS

Idioma: Español
Referencias bibliográficas: 58
Paginas: 217-228
Archivo PDF: 312.18 Kb.


RESUMEN

La diabetes mellitus tipo 2 constituye una de las enfermedades crónicas con mayor prevalencia a nivel mundial y se asocia a múltiples factores de riesgo cardiovascular y a un incremento del riesgo de mortalidad por enfermedad cardiovascular. Se revisaron 58 referencias bibliográficas con el objetivo de describir elementos importantes para la estratificación del riesgo cardiovascular y en el tratamiento de algunos factores de riesgo en los pacientes con esta enfermedad.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. American Diabetes Association. Standards ofmedical care in diabetes 2014. Diabetes Care. 2014;37(Supl 1):S14-80. [DOI]

  2. American Diabetes Association. Standards ofmedical care in diabetes 2015 abridged for primary care providers. Clin Diabetes. 2015;33(2):97-111. [DOI]

  3. International Diabetes Federation. IDF DiabetesAtlas: Eighth Edition 2017 [Internet]. Bruselas: International Diabetes Federation; 2017 [citado 21Ago 2020]. Disponible en:https://diabetesatlas. org/upload/resources/previous/files/8/IDF_DA_8e-EN-final. pdf

  4. Evans JM, Wang J, Morris AD. Comparison ofcardiovascular risk between patients with type 2diabetes and those who had had a myocardial infarction: cross sectional and cohort studies. BMJ. 2002;324(7343):939-42. [DOI]

  5. Lee C, Joseph L, Colosimo A, Dasgupta K. Mortality in diabetes compared with previous cardiovascular disease: a gender-specific meta-analysis. Diabetes Metab. 2012;38(5):420-7. [DOI]

  6. Stam-Slob MC, van der Graaf Y, de Borst GJ,Cramer MJ, Kappelle LJ, Westerink J, et al. Effectof Type 2 Diabetes on Recurrent Major Cardiovascular Events for Patients With SymptomaticVascular Disease at Different Locations. DiabetesCare. 2015;38(8):1528-35. [DOI]

  7. Standards of medical care in diabetes 2015: summary of revisions. Diabetes Care. 2015;38(Supl 1):54. [DOI]

  8. American Diabetes Association. 9. CardiovascularDisease and Risk Management: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018;41(Supl 1):S86-104. [DOI]

  9. Goff DC, Lloyd-Jones DM, Bennett G, Coady S,D'Agostino RB, Gibbons R, et al. 2013 ACC/AHAguideline on the assessment of cardiovascularrisk: a report of the American College of Cardiology/American Heart Association Task Force onPractice Guidelines. Circulation. 2014;129(25 Supl2):S49-73. [DOI]

  10. Tanaka S, Tanaka S, Iimuro S, Yamashita H, Katayama S, Akanuma Y, et al. Predicting macro andmicrovascular complications in type 2 diabetes:the Japan Diabetes Complications Study/the Japanese Elderly Diabetes Intervention Trial risk engine. Diabetes Care. 2013;36(5):1193-9. [DOI]

  11. Lopes-Virella MF, Carter RE, Gilbert GE, Klein RL, Jaffa M, Jenkins AJ, et al. Risk factors related toinflammation and endothelial dysfunction in theDCCT/EDIC cohort and their relationship withnephropathy and macrovascular complications. Diabetes Care. 2008;31(10):2006-12. [DOI]

  12. Griffin E, Re A, Hamel N, Fu C, Bush H, McCaffreyT, et al. A link between diabetes and atherosclerosis: Glucose regulates expression of CD36 at thelevel of translation. Nat Med. 2001;7(7):840-6. [DOI]

  13. Standards of Medical Care in Diabetes-2017: Summary of Revisions. Diabetes Care. 2017;40(Supl1):S4-5. [DOI]

  14. Moons KG, Kengne AP, Grobbee DE, Royston P,Vergouwe Y, Altman DG, et al. Risk predictionmodels: II. External validation, model updating,and impact assessment. Heart. 2012;98(9):691-8. [DOI]

  15. Piepoli MF, Hoes AW, Agewall S, Albus C, BrotonsC, Catapano AL, et al. Guía ESC 2016 sobre prevención de la enfermedad cardiovascular en lapráctica clínica. Rev Esp Cardiol. 2016;69(10):939. e1-87. [DOI]

  16. Arnett DK, Blumenthal RS, Albert MA, BurokerAB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHAGuideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart AssociationTask Force on Clinical Practice Guidelines. J AmColl Cardiol. 2019;74(10):1376-414. [DOI]

  17. De Cosmo S, Copetti M, Lamacchia O, Fontana A,Massa M, Morini E, et al. Development and validation of a predicting model of all-cause mortalityin patients with type 2 diabetes. Diabetes Care. 2013;36(9):2830-5. [DOI]

  18. Piniés JA, González-Carril F, Arteagoitia JM, Irigoien I, Altzibar JM, Rodriguez-Murua JL, et al. Development of a prediction model for fatal andnon-fatal coronary heart disease and cardiovascular disease in patients with newly diagnosedtype 2 diabetes mellitus: the Basque Country Prospective Complications and Mortality Study riskengine (BASCORE). Diabetologia. 2014;57(11):2324-33. [DOI]

  19. Piniés JA, Gonzalez-Carril F, Arteagoitia JM. Escalas de cálculo del riesgo cardiovascular para pacientes con diabetes. ¿Qué son y de qué nos sirven? Av Diabetol. 2015;31(3):102-12. [DOI]

  20. JBS3 Board. Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart. 2014;100(Supl 2):II1-II67. [DOI]

  21. Hajifathalian K, Ueda P, Lu Y, Woodward M, Ahmadvand A, Aguilar-Salinas CA, et al. A novel riskscore to predict cardiovascular disease risk in national populations (Globorisk): a pooled analysisof prospective cohorts and health examinationsurveys. Lancet Diabetes Endocrinol. 2015;3(5):339-55. [DOI]

  22. Aboyans V, Ricco JB, Bartelink ML, Björck M,Brodmann M, Cohnert T, et al. Guía ESC 2017 sobre el diagnóstico y tratamiento de la enfermedadarterial periférica, desarrollada en colaboracióncon la European Society for Vascular Surgery(ESVS). Rev Esp Cardiol. 2018;71(2):111. e1-69. [DOI]

  23. Association American Diabetes. Updates to theStandards of Medical Care in Diabetes-2018. Diabetes Care. 2018;41(9):2045-7. [DOI]

  24. Jiménez-Corona A, Aguilar-Salinas C. A, Rojas-Martínez R, Hernández-Ávila M. Diabetes mellitus tipo 2 y frecuencia de acciones para su prevencióny control. Salud Publica Mex. 2013;55(Supl 2):S137-43. [DOI]

  25. Schellenberg ES, Dryden DM, Vandermeer B, HaC, Korownyk C. Lifestyle interventions for patients with and at risk for type 2 diabetes: a systematic review and meta-analysis. Ann InternMed. 2013;159(8):543-51. [DOI]

  26. Thomas RJ, Balady G, Banka G, Beckie TM, ChiuJ, Gokak S, et al. 2018 ACC/AHA Clinical Performance and Quality Measures for Cardiac Rehabilitation: A Report of the American College of Cardiology/American Heart Association Task Forceon Performance Measures. J Am Coll Cardiol. 2018;71(16):1814-37. [DOI]

  27. Rydén L, Grant PJ, Anker SD, Berne C, CosentinoF, Danchin N, et al. Guía de práctica Clínica de laESC sobre diabetes, prediabetes y enfermedadcardiovascular, en colaboración con la EuropeanAssociation for the Study of Diabetes. Rev EspCardiol. 2014;67(2):136. e1-56. [DOI]

  28. Williams B, Mancia G, Spiering W, Rosei EA, AziziM, Burnier M, et al. Guía ESC/ESH 2018 sobre eldiagnóstico y tratamiento de la hipertensión arterial. Rev Esp Cardiol. 2019;72(2):160. e1-78. [DOI]

  29. Cushman WC, Evans GW, Byington RP, Goff DC,Grimm RH, Cutler JA, et al. Effects of intensiveblood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1575-85. [DOI]

  30. Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood pressure lowering in type 2diabetes: a systematic review and meta-analysis. JAMA. 2015;313(6):603-15. [DOI]

  31. Carey RM, Whelton PK. Prevention, Detection,Evaluation, and Management of High Blood Pressure in Adults: Synopsis of the 2017 AmericanCollege of Cardiology/American Heart Association Hypertension Guideline. Ann Intern Med. 2018;168(5):351-8. [DOI]

  32. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutideand Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-22. [DOI]

  33. Moura CS, Rosenberg ZB, Abrahamowicz M, Bernatsky S, Behlouli H, Pilote L. Treatment discontinuation and clinical events in type 2 diabetespatients treated with dipeptidyl peptidase-4 inhibitors or NPH insulin as third-line therapy. J Diabetes Res [Internet]. 2018 [citado 5 Sep 2020];2018:4817178. Disponible en:https://doi. org/10. 1155/2018/4817178

  34. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D,Fulcher G, Erondu N, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644-57. [DOI]

  35. Zinman B, Wanner C, Lachin JM, Fitchett D,Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-28. [DOI]

  36. Fitchett D, Butler J, van de Borne P, Zinman B,Lachin JM, Wanner C, et al. Effects of empagliflozin on risk for cardiovascular death and heartfailure hospitalization across the spectrum ofheart failure risk in the EMPA-REG OUTCOME®trial. Eur Heart J. 2018;39(5):363-70. [DOI]

  37. Stone NJ, Robinson JG, Lichtenstein AH, BaireyMerz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascularrisk in adults: a report of the American College ofCardiology/American Heart Association TaskForce on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889-934. [DOI]

  38. Huo R, Du T, Xu Y, Xu W, Chen X, Sun K, et al. Effects of Mediterranean-style diet on glycemiccontrol, weight loss and cardiovascular risk factors among type 2 diabetes individuals: a metaanalysis. Eur J Clin Nutr. 2015;69(11):1200-8. [DOI]

  39. Way KL, Hackett DA, Baker MK, Johnson NA. TheEffect of Regular Exercise on Insulin Sensitivity inType 2 Diabetes Mellitus: A Systematic Reviewand Meta-Analysis. Diabetes Metab J. 2016;40(4):253-71. [DOI]

  40. Yusuf S, Bosch J, Dagenais G, Zhu J, Xavier D, LiuL, et al. Cholesterol Lowering in Intermediate-RiskPersons without Cardiovascular Disease. N Engl JMed. 2016;374(21):2021-31. [DOI]

  41. Grundy SM, Stone NJ. 2018 Cholesterol ClinicalPractice Guidelines: Synopsis of the 2018 American Heart Association/American College of Cardiology/Multisociety Cholesterol Guideline. AnnIntern Med. 2019;170(11):779-83. [DOI]

  42. Karlson BW, Wiklund O, Palmer MK, Nicholls SJ,Lundman P, Barter PJ. Variability of low-densitylipoprotein cholesterol response with differentdoses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER. Eur Heart J Cardiovasc Pharmacother. 2016;2(4):212-7. [DOI]

  43. de Vries FM, Denig P, Pouwels KB, Postma MJ,Hak E. Primary prevention of major cardiovascular and cerebrovascular events with statins in diabetic patients: a meta-analysis. Drugs. 2012;72(18):2365-73. [DOI]

  44. Cannon CP, Blazing MA, Giugliano RP, McCagg A,White JA, Theroux P, et al. Ezetimibe Added toStatin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015;372(25):2387-97. [DOI]

  45. Mortensen MB, Afzal S, Nordestgaard BG, Falk E. The high-density lipoprotein-adjusted SCOREmodel worsens SCORE-based risk classification ina contemporary population of 30,824 Europeans:the Copenhagen General Population Study. EurHeart J. 2015;36(36):2446-53. [DOI]

  46. Khan AR, Bavishi C, Riaz H, Farid TA, Khan S, Atlas M, et al. Increased Risk of Adverse Neurocognitive Outcomes With Proprotein ConvertaseSubtilisin-Kexin Type 9 Inhibitors. Circ Cardiovasc Qual Outcomes [Internet]. 2017 [citado 16Sep 2020];10(1):e003153. Disponible en:https://doi. org/10. 1161/circoutcomes. 116. 003153

  47. Robinson JG, Rosenson RS, Farnier M, ChaudhariU, Sasiela WJ, Merlet L, et al. Safety of Very LowLow-Density Lipoprotein Cholesterol Levels WithAlirocumab: Pooled Data From Randomized Trials. J Am Coll Cardiol. 2017;69(5):471-82. [DOI]

  48. Sabatine MS, Giugliano RP, Keech AC, HonarpourN, Wiviott SD, Murphy SA, et al. Evolocumab andClinical Outcomes in Patients with CardiovascularDisease. N Engl J Med. 2017;376(18):1713-22. [DOI]

  49. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Prevalence of metabolic syndrome in type 2 diabetes mellitus patients. Int J Appl Basic Med Res. 2015;5(2):133-8. [DOI]

  50. 50.Nsiah K, Shang VO, Boateng KA, Mensah FO. Prevalence of metabolic syndrome in type 2 diabetes mellitus patients. Int J Appl Basic Med Res.2015;5(2):133-8. [DOI]

  51. Riddle MC, Bakris G, Boulton AJ, Blonde L, D'Alessio D, Greene EL, et al. Big Topics for DiabetesCare in 2018: Clinical Guidelines, Costs of Diabetes, and Information Technology. Diabetes Care.2018;41(7):1327-9. [DOI]

  52. Khera R, Murad MH, Chandar AK, Dulai PS, WangZ, Prokop LJ, et al. Association of Pharmacological Treatments for Obesity With Weight Loss andAdverse Events: A Systematic Review and Metaanalysis. JAMA. 2016;315(22):2424-34. [DOI]

  53. Cai X, Yang W, Gao X, Zhou L, Han X, Ji L. Baseline Body Mass Index and the Efficacy of Hypoglycemic Treatment in Type 2 Diabetes: A MetaAnalysis. PLoS One [Internet]. 2016 [citado 21Sep 2020];11(12):e0166625. Disponible en:https://doi.org/10.1371/journal.pone.0166625

  54. Rubino F, Nathan DM, Eckel RH, Schauer PR,Alberti KG, Zimmet PZ, et al. Metabolic Surgery inthe Treatment Algorithm for Type 2 Diabetes: AJoint Statement by International Diabetes Organizations. Diabetes Care. 2016;39(6):861-77. [DOI]

  55. Wycherley TP, Clifton PM, Noakes M, BrinkworthGD. Weight loss on a structured hypocaloric dietwith or without exercise improves emotional distress and quality of life in overweight and obesepatients with type 2 diabetes. J Diabetes Investig.2014;5(1):94-8. [DOI]

  56. Drugs. Phentermine FDA prescribing information,side effects and uses. Drugs [Internet].2020 [citado 22 Sep 2020]. Disponible en:https://www.drugs.com/pro/phentermine

  57. Pi-Sunyer X, Astrup A, Fujioka K, Greenway F,Halpern A, Krempf M, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in WeightManagement. N Engl J Med. 2015;373(1):11-22.[DOI]

  58. Wong RH, Scholey A, Howe PR. Assessing premorbid cognitive ability in adults with type 2 diabetes mellitus a review with implications for future intervention studies. Curr Diab Rep [Internet]. 2014 [citado 22 Sep 2020];14(11):547. Disponible en: https://doi.org/10.1007/s11892-014-0547-4




2020     |     www.medigraphic.com